Abstract
Oral chemotherapy offers several potential benefits over intravenous treatment, and the majority of patients would prefer oral therapy provided that it does not compromise efficacy. We review the evidence that oral fluoropyrimidines can replace intravenous 5-fluorouracil (5-FU) in the adjuvant therapy of colon cancer, without loss of efficacy, while at the same time improving tolerability and reducing the use of medical resources. The addition of oxaliplatin to intravenous 5-FU improves disease-free survival in patients with resected colon cancer and both uracil/tegafur and capecitabine can be combined safely with oxaliplatin. The effect on efficacy of replacing intravenous 5-FU with oral fluoropyrimidines in combination regimens is being assessed in ongoing trials.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
